Laidlaw Capital Markets is Financial Advisor on MEI Pharma Inc’s $52,325,000 Follow-On Offering
Laidlaw Capital Markets is pleased to be Financial Advisor on the MEI Pharma Inc’s $52,325,000 Follow-On Offering alongside Jefferies, Stifel, and Wells Fargo.” Link: https://www.meipharma.com/press-releases/mei-pharma-announces-closing-public-offering-common-stock-0
Laidlaw Venture Partners’ portfolio company Amesite CEO, Dr. Ann Marie Sastry, back on CNBC’s Squawk Box.
Ann Marie Sastry, founder and CEO of Amesite, joins “Squawk Box” to discuss how the Covid-19 pandemic is changing remote learnings for students and workers looking to continue their education.”
Laidlaw Venture Partners Continues Strategic Growth with Addition of Jeff Conroy and George Serafin to its Board of Advisors
Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeff Conroy and George Serafin to its Board of Advisors. As industry leaders in Business Development and Regulatory/Compliance...
Laidlaw served as Co-Manager on the $50,000,000 Follow-On Offering for Soleno Therapeutics (SLNO) with Guggenheim Partners
Laidlaw is pleased to have Co-Managed a $50,000,000 deal for Soleno Therapeutics (SLNO) with Guggenheim Partners. View Press Release
Laidlaw served as Sole Book-Runner on the $14,375,000 Offering for Evoke Pharma (EVOK)
Laidlaw Capital Markets is pleased to have acted as the Sole Book-Runner on the $14,375,000 Follow-On Offering for Evoke Pharma (EVOK). Evoke has been a partner for years now and we are excited for their Read More...
Laidlaw served as Financial Advisor on the $20,000,000 Offering for Delcath Systems (DCTH)
Laidlaw Capital Markets is pleased to have served as a Financial Advisor to Delcath Systems on their $20,000,000 Follow-on Offering alongside Canaccord Genuity and Roth Capital
Stay In Touch